LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...
Portage Biotech Inc.: Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data ...
Portage Biotech presents preclinical data for PORT-7
Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...
Portage Biotech stock soars on promising preclinical data
Investing.com -- Shares of Portage Biotech Inc. (NASDAQ: PRTG) surged 29% following the presentation of new preclinical data for its mesothelioma treatment, PORT-7. The company unveiled these findings ...
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 ...
The American Journal of Managed Care17h
Optimizing Patient Selection for CAR T, Bispecifics, Mitigates Adverse Events in High-Risk MM
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.